AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update

AlloVir, Inc. (NASDAQ:ALVR) experienced a notable decline in short interest in January. As of January 31st, the total short interest stood at 59,500 shares, reflecting a decrease of 14.0% compared to the January 15th figure of 69,200 shares. Currently, around 2.6% of the company’s shares are sold short. Given the average daily trading volume of 26,100 shares, the short-interest ratio is estimated at 2.3 days.

Investors' Activities in AlloVir

Recently, institutional investors and hedge funds have adjusted their positions in AlloVir. Northern Trust Corp increased its holding in the company by 0.8% during the fourth quarter, now owning 159,685 shares valued at approximately $67,000 after acquiring an additional 1,267 shares. Additionally, Jane Street Group LLC boosted its stake in AlloVir by 47.8%, attaining ownership of 123,159 shares worth about $52,000 after purchasing 39,808 shares. Raymond James Financial Inc. established a new position in AlloVir during the same quarter, valued at roughly $25,000. Furthermore, Gilead Sciences Inc. entered a new investment in AlloVir, amounting to around $6,987,000. Overall, hedge funds and other institutional investors own approximately 66.05% of AlloVir’s stock.

Current Stock Performance of AlloVir

On Friday, ALVR stock opened at $9.90. The company currently has a market capitalization of $49.80 million, a price-to-earnings ratio of -0.49, and a beta of 0.65. The fifty-day simple moving average for AlloVir's stock is $10.10, while the 200-day simple moving average is $14.58. Over the past year, the stock has recorded a low of $7.96 and a high of $24.15.

About AlloVir, Inc.

AlloVir, Inc. is involved in the research, development, and commercialization of off-the-shelf virus-specific T cell (VST) therapies aimed at preventing and treating severe diseases associated with viral infections. The company's objective focuses on creating innovative cell therapies that restore natural immunity in individuals with severely compromised immune systems.

Additional Information

• Five better-performing stocks compared to AlloVir
• Key insights for investors to outperform the market
• Recent decline of Symbotic shares; should you be cautious or bold?
• Understanding secondary public offerings: essential investor knowledge
• High-yield healthcare: three stocks offering strong dividends
• What does a stock split signify?
• Exceeding expectations: three top stocks in discount retail

AlloVir, Investors, Stocks